Nanotechnology Now

Our NanoNews Digest Sponsors


Heifer International

Wikipedia Affiliate Button


DHgate

Home > News > American Pharmaceutical Partners Reports Tolerability of High Dose

June 8th, 2004

American Pharmaceutical Partners Reports Tolerability of High Dose

Abstract:
Abraxis Oncology, a division of American Pharmaceutical Partners, Inc. today reported results of a Phase I dose-escalation study of ABRAXANETM (albumin nanoparticle paclitaxel) that indicated this investigational drug is well-tolerated at high doses in a weekly dosing schedule for non-hematologic malignancies such as lung, ovarian and metastatic breast cancer and patients who have had prior chemotherapies.

Source:
APP

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

How cancer cells spread and squeeze through tiny blood vessels (video) June 30th, 2016

Building a smart cardiac patch: 'Bionic' cardiac patch could one day monitor and respond to cardiac problems June 28th, 2016

Nanoscientists develop the 'ultimate discovery tool': Rapid discovery power is similar to what gene chips offer biology June 25th, 2016

Nanotechnology and math deliver two-in-one punch for cancer therapy resistance June 24th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic